March 23, 2023
National Cancer Institute (NCI)
The National Cancer Institute (NCI) Division of Cancer Prevention (DCP) is soliciting feedback, comments, innovative ideas, and strategies to guide its efforts in expanding and improving the development of the molecular cancer prevention and cancer interception research workforce in the United States. This includes education and training needs for both early- (e.g., including pre- and postdoctoral fellows, early-stage investigators) and mid-career scientists who are passionate about cancer prevention or may be seeking to enter the fields of molecular cancer prevention and cancer interception (including foundational/basic, translational, and clinical research), as well as specific research areas within these fields. NCI also seeks input on how to best support successful career transitions for molecular cancer prevention and cancer interception scientists to enable these scientists to become leaders in the broader cancer prevention research community, and across various career sectors (i.e., academia, industry, and government).
NCI seeks input from key extramural community stakeholders, including early-career scientists, biomedical faculty, training program directors, scientific societies, and academic institutions, as well as interested members of the public, on strategies to expand and enhance development of the molecular cancer prevention and cancer interception workforce. Within the broader area of cancer prevention, molecular cancer prevention and cancer interception includes the translation of the biological mechanisms and processes underlying carcinogenesis and cancer towards interventions focused on cancer prevention, interception, screening, and early detection. The goal is to use these mechanistic understandings to interrupt or intervene in the carcinogenic process at the earliest point possible. Molecular cancer prevention and cancer interception research encompasses the full translational spectrum, from preclinical (e.g., cell and tissue culture, animal models) to clinical research, and requires contributions from scientists across a variety of different scientific disciplines (e.g., fundamental basic science, epidemiology, behavioral, and clinical research). Areas of interest for this RFI include, but are not limited to, education and training needs, mentoring, and utilization of current funding mechanisms.
Topics that could be addressed include, but are not limited to, the following areas:
A:) Developing the Molecular Cancer Prevention and Cancer Interception Research Workforce – General Topics
B:) Education and Training Needs for Early- and Mid-Career Molecular Cancer Prevention and Cancer Interception Scientists
C:) Molecular Cancer Prevention and Cancer Interception Research Education and Training Needs for Physician-Scientists
D:) NCI-supported Cancer Prevention Research Training and Education Programs
How to Submit a Response
Responses to this RFI will be accepted through the Strategies to Expand and Enhance Development of the Molecular Cancer Prevention and Cancer Interception Research Workforce webform Responders are free to address any or all of the questions listed above. The webform is the preferred mode of input, but a file with associated answers may also be sent to NCIDCPworkforce@mail.nih.gov
Responses will be accepted through 11:59 p.m. Eastern Standard Time on June 30, 2023.
Responses to this RFI are entirely voluntary and may be submitted anonymously.
Do not include any proprietary, classified, confidential, trade secret, or sensitive information in your response. The responses will be reviewed by NIH staff, and individual feedback will not be provided to any responder except as described above. The Government will use the information submitted in response to this RFI at its discretion. Any identifiers (e.g., names, institutions, e-mail addresses, etc.) will be removed when responses are compiled. The Government reserves the right to use only the processed, anonymized results on public NIH websites, in reports, in summaries of the state of the science, in any possible resultant solicitation(s), grant(s), or cooperative agreement(s), or in the development of future funding opportunity announcements.
This RFI is for information and planning purposes only and shall not be construed as a solicitation, grant, or cooperative agreement, or as an obligation on the part of the Federal Government, the NIH, or individual NIH Institutes and Centers to provide support for any ideas identified in response to it. The Government will not pay for the preparation of any information submitted or for the Governments use of such information. No basis for claims against the U.S. Government shall arise as a result of a response to this RFI or from the Governments use of such information.
NIH looks forward to your input, and we hope that you will share this RFI document with your colleagues.
National Cancer Institute (NCI)